Novo Nordisk Reveals Positive Phase III Results from Semaglutide and Xultophy

Novo Nordisk presented two separate Phase III studies in type 2 diabetes—evaluating semaglutide and Xultophy—at the annual meeting of the European Association for the Study of Diabetes.

Once-weekly semaglutide significantly improved glycemic control compared to placebo, administered as an add-on to basal insulin alone or in combination with metformin, in adults with type 2 diabetes for an average duration of 13 years. Adults treated with semaglutide also achieved superior weight loss.

The 30-week Phase IIIa trial showed that patients treated with semaglutide at 0.5 mg and 1.0 mg doses achieved statistically significant and superior HbA1c reductions of 1.4 and 1.8 percent, respectively, compared to 0.1 percent reduction with placebo.